Leerink Partners Downgrades Centessa Pharmaceuticals to Market Perform, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 72.8%

Neg 72.8% Neu 0% Pos 0%

Leerink Partners analyst David Risinger downgrades Centessa Pharmaceuticals (NASDAQ:CNTA) from Outperform to Market Perform and raises the price target from $36 to $40.